Skip to content
About us
Our DNA
Board members
Our leadership
Partners
Pipeline
VTX-801 – Wilson’s disease
> VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
VTX-802 & VTX-803 – PFIC
VTX-804 – Citrullinemia Type 1
VTX–806 – Cerebrotendinous Xanthomatosis
Investors
News
Events
Patients & Families
Patient’s Stories
Patient advocacy
Patient & Families ressources
Compassionate Use and Expanded Access
Work at Vivet
Menu
About us
Our DNA
Board members
Our leadership
Partners
Pipeline
VTX-801 – Wilson’s disease
> VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
VTX-802 & VTX-803 – PFIC
VTX-804 – Citrullinemia Type 1
VTX–806 – Cerebrotendinous Xanthomatosis
Investors
News
Events
Patients & Families
Patient’s Stories
Patient advocacy
Patient & Families ressources
Compassionate Use and Expanded Access
Work at Vivet
Vivet will be at BIO Europe in Berlin on November 6-8th
BACK
Vivet will be at BIO Europe in Berlin on November 6-8th
Vivet Therapeutics will participate to
BIO Europe
in Berlin on November 6-8th 2017.
Latest events
CTX Scientific & Family Meeting on the 28 June at 13.25 CST in Itasca, Illinois!
26 June 2024
EASL Congress 2024, the home of Hepatology, from 5-8 June in Milan, Italy
3 June 2024
4th Annual Gene Therapy Patient Engagement Summit
24 May 2024
5th Annual Gene Therapy Analytical Development Europe Summit
17 May 2024
Genome Regulation and Cellular Fates in Homeostasis and Disease conference
13 May 2024
BioEquity Europe 2024, from 12 – 14 May in San Sebastian, Spain!
7 May 2024
All Events